Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in Parkinson's Disease
NCT04459052Phase 2Active, not recruiting
- Sponsor
- Thomas Jefferson University
- Start
- Apr 2020
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acetylcysteine in Parkinson's disease (PD), sponsored by Thomas Jefferson University. Started Apr 2020; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04459052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04459052.